Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 17, Issue 1-2, 2016, Pages 119-127

  Boylan, Kevin ^a   Levine, Todd ^b   Lomen Hoerth, Catherine ^c   Lyon, Mary ^d   Maginnis, Kimberly ^d   Callas, Peter ^e   Gaspari, Celeste ^e   Tandan, Rup ^f  

^a MAYO CLINIC   (United States)

^b Phoenix Neurological Associates   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALS Association   (United States)

^e UNIVERSITY OF VERMONT   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Amyotrophic lateral sclerosis; health care economics; multidisciplinary care

Indexed keywords

RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; GASTROSTOMY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONINVASIVE VENTILATION; PATIENT CARE; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALARY; TRACHEOSTOMY; UNITED STATES; ECONOMICS; HOSPITAL ADMISSION; MIDDLE AGED; NEUROLOGY; OUTPATIENT DEPARTMENT; PREVALENCE; PROTOCOL COMPLIANCE; STANDARDS; STATISTICS AND NUMERICAL DATA; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEUROLOGY; PATIENT CARE TEAM; PATIENT SATISFACTION; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROSPECTIVE STUDIES; UNITED STATES; WAITING LISTS;

EID: 84955705481     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2015.1091478     Document Type: Article

References (22)

1. Chio A, Bottacchi E, Buffa C, Mutani R, Mora G. Positive effects of tertiary centers for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006; 77: 948-50.
2. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry. 2003; 74: 1258-61.
3. van den Berg JP, Kalmijn S, Lindeman E, Veldink JH, de Visser M, van der Graaff MM, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology. 2005; 65: 1264-7.
4. The ALS Association. Certified Center Program. 2014; Available from: http://www.alsa.org/community/certified-centers/.
5. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009; 73: 1218-26.
6. Gladman M, Dharamshi C, Zinman L. Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15: 426-32.
7. Lopez-Bastida J, Perestelo-Perez L, Monton-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 2009; 10: 237-43.
8. van der Steen I, van den Berg JP, Buskens E, Lindeman E, van den Berg LH. The costs of amyotrophic lateral sclerosis, according to type of care. Amyotroph Lateral Scler. 2009; 10: 27-34.
9. Boylan K, Levine T, Lomen-Hoerth C, Lyon M, Tandan R., editors. Cost assessment of multidisciplinary clinics adhering to AAN ALS practice parameters. 23rd International Symposium on ALS/MND. 2012; Chicago, IL.
10. Tandan R, Boylan K, Levine T, Lomen-Hoerth C, Callas P, Maginnis K, et al. Prospective Study of Cost of Care at Multidisciplinary Centers Adhering to AAN Amyotrophic Lateral Sclerosis (ALS) Practice Parameters. Neurology. 2014; 82 (Supplement 10): S49.001.
11. The National Fair Labor Standards Act. Accessed 3 July 2015; Available at: https://en.wikipedia.org/wiki/Fair-Labor-Standards-Act
12. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169: 13-21.
13. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998; 55: 526-8.
14. Miller RG, Anderson F, Brooks BR, Mitsumoto H, Bradley WG, Ringel SP. Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database. Ann Neurol. 2009; 65 (Suppl 1): S24-8.
15. Woolley M, Ringel SP, Group BS., editors. Health resource utilization and the cost of care in ALS. 8th International ALS/MND Symposium; 1997; Glasgow, Scotland
16. Lechtzin N, Wiener CM, Clawson L, Chaudhry V, Diette GB. Hospitalization in amyotrophic lateral sclerosis: causes, costs, and outcomes. Neurology. 2001; 56: 753-7.
17. Munsat TL, Riviere M, Swash M, Leclerc C. Economic burden of amyotrophic lateral sclerosis in the United Kingdom. J Med Econ. 1998; 1: 235-45.
18. Athanasakis K, Kyriopoulos I-I, Sideris M, Rentzos M, Evdokimidis J, Kyriopoulos J. Investigating the economic burden of ALS in Greece: a cost-of-illness approach. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 14: 1-2.
19. Connolly S, Heslin C, Mays I, Corr B, Normand C, Hardiman O. Health and social care costs of managing amyotrophic lateral sclerosis (ALS): an Irish perspective. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 6: 1-5.
20. Jennum P, Ibsen R, Pedersen SW, Kjellberg J. Mortality, health, social and economic consequences of amyotrophic lateral sclerosis: a controlled national study. J Neurol. 2013; 260: 785-93.
21. Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schroder R, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010; 257: 15-23.
22. Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014; 49: 431-8.